Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | APEX1 | P27695 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.73 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301203 | 1.00 | MEN1 (0.76) | MEN1KMT2ALMNAPOLBPKM | |
| SCHEMBL7303163 | 0.91 | HDAC3 (0.86) | MEN1KMT2ALMNAHDAC3HDAC6 | |
| SCHEMBL9115945 | 0.90 | POLB (0.76) | MEN1KMT2ALMNAPOLBPKM | |
| SCHEMBL15651819 | 0.88 | PTGS1 (0.73) | MEN1KMT2ALMNAPOLBPKM | |
| SCHEMBL907217 | 0.87 | EPHX2 (0.60) | MEN1KMT2ALMNAPOLBPKM | |
| SCHEMBL9681496 | 0.87 | POLB (1.00) | MEN1KMT2ALMNAPOLBPKM | |
| SCHEMBL137276 | 0.87 | POLB (1.00) | MEN1KMT2ALMNAPOLBPKM | |
| SCHEMBL30319980 | 0.87 | POLB (1.00) | MEN1KMT2ALMNAPOLBPKM | |
| SCHEMBL2128727 | 0.87 | POLB (1.00) | MEN1KMT2ALMNAPOLBPKM | |
| SCHEMBL1353478 | 0.87 | POLB (1.00) | MEN1KMT2ALMNAPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| WO-2019233474-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2019-12-12 | — | — | WO | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| EP-0358118-B1 | Phenylamides - process for their preparation as well as a drug containing those compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5135949-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1992-08-04 | — | — | US | disclosed |
| EP-0358118-A1 | Phenylamides - process for their preparation as well as a drug containing those compounds | Roche Diagnostics GmbH (DE) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MEN1 544/4885KMT2A 921/4885LMNA 3015/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MEN1 1218/4885KMT2A 1345/4885LMNA 3243/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MEN1 544/4885KMT2A 921/4885LMNA 3015/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MEN1 636/4885KMT2A 929/4885LMNA 3115/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MEN1 636/4885KMT2A 929/4885LMNA 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.